About AiCuris
AiCuris is a company based in Wuppertal (Germany) founded in 2006 was acquired by Asahi Kasei in February 2026. AiCuris has raised $74.8 million across 4 funding rounds from investors including Asahi Kasei. The company has 61 employees as of December 31, 2020. AiCuris offers products and services including AIC468 and Pipeline Products. AiCuris operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter Wuppertal, Germany
- Employees 61 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aicuris Anti-Infective Cures Gmbh
-
Annual Revenue
$69.77 M (USD)-48as on Dec 31, 2018
-
Net Profit
$10.06 M (USD)-74as on Dec 31, 2019
-
EBITDA
$10.06 M (USD)-74as on Dec 31, 2019
-
Total Equity Funding
$74.8 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
61
as on Dec 31, 2020
-
Acquired by
Asahi Kasei
(Feb 26, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AiCuris
AiCuris offers a comprehensive portfolio of products and services, including AIC468 and Pipeline Products.
Targets BK Virus infections in kidney transplant recipients.
Advances anti-viral therapies for immunocompromised patients.
Funding Insights of AiCuris
AiCuris has successfully raised a total of $74.8M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AiCuris
AiCuris has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Asahi Kasei.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CDMO focused on manufacturing of liquid, solid & injectable drug formulations
|
Locked | Locked | Locked |
Investor details for AiCuris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AiCuris
Investment portfolio details for AiCuris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AiCuris
Detailed financials for AiCuris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aicuris Comparisons
Peer comparison for AiCuris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AiCuris
AiCuris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
|
| Locked | Locked | Locked |
Developer of computationally designed VLP vaccines for treating multiple infections
|
Detailed competitors of AiCuris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aicuris
Complete news archive for AiCuris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AiCuris
AiCuris was founded in 2006 and raised its 1st funding round 4 years after it was founded.
AiCuris is headquartered in Wuppertal, Germany. It is registered at Wuppertal, North Rhine-westphalia, Germany.
Holger Zimmermann is the current CEO of AiCuris.
AiCuris is a funded company, having raised a total of $74.8M across 4 funding rounds to date.
As of Dec 31, 2020, the latest employee count at AiCuris is 61.
Annual revenue of AiCuris is $69.77M as on Dec 31, 2018.
AiCuris was established in 2006 in Wuppertal, Germany, as a pharmaceutical firm focused on antiviral and antibacterial agents targeting life-threatening infections. Therapeutics in the pipeline include Prevymis (AIC246), a quinazoline-based CMV terminase inhibitor approved for human cytomegalovirus treatment; AIC316, advanced to phase II for herpes simplex; and AIC649, in phase I for hepatitis B virus. Operations center on drug development for unmet needs in infectious diseases.
AiCuris's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
AiCuris offers AIC468 and Pipeline Products.
AiCuris has 1 investor. Key investors include Asahi Kasei.